Efficacy and Tolerability of the New Antiepileptic Drugs, I: Treatment of New-Onset Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society
dc.contributor.author | French, Jacqueline A. | en_US |
dc.contributor.author | Kanner, Andres M. | en_US |
dc.contributor.author | Bautista, Jocelyn | en_US |
dc.contributor.author | Abou-Khalil, Bassel W. | en_US |
dc.contributor.author | Browne, Thomas | en_US |
dc.contributor.author | Harden, Cynthia L. | en_US |
dc.contributor.author | Theodore, William H. | en_US |
dc.contributor.author | Bazil, Carl | en_US |
dc.contributor.author | Stern, John | en_US |
dc.contributor.author | Schachter, Steven C. | en_US |
dc.contributor.author | Bergen, Donna | en_US |
dc.contributor.author | Hirtz, Deborah | en_US |
dc.contributor.author | Montouris, Georgia D. | en_US |
dc.contributor.author | Nespeca, Mark | en_US |
dc.contributor.author | Gidal, Barry | en_US |
dc.contributor.author | Marks, William J. | en_US |
dc.contributor.author | Turk, William R. | en_US |
dc.contributor.author | Fischer, James H. | en_US |
dc.contributor.author | Bourgeois, Blaise | en_US |
dc.contributor.author | Wilner, Andrew | en_US |
dc.contributor.author | Faught, R. Edward | en_US |
dc.contributor.author | Sachdeo, Rajesh C. | en_US |
dc.contributor.author | Beydoun, Ahmad A. | en_US |
dc.contributor.author | Glauser, Tracy A. | en_US |
dc.date.accessioned | 2010-04-01T14:46:59Z | |
dc.date.available | 2010-04-01T14:46:59Z | |
dc.date.issued | 2004-05 | en_US |
dc.identifier.citation | French, Jacqueline A.; Kanner, Andres M.; Bautista, Jocelyn; Abou-Khalil, Bassel; Browne, Thomas; Harden, Cynthia L.; Theodore, William H.; Bazil, Carl; Stern, John; Schachter, Steven C.; Bergen, Donna; Hirtz, Deborah; Montouris, Georgia D.; Nespeca, Mark; Gidal, Barry; Marks, William J.; Turk, William R.; Fischer, James H.; Bourgeois, Blaise; Wilner, Andrew; Faught, R. Edward; Sachdeo, Rajesh C.; Beydoun, Ahmad; Glauser, Tracy A. (2004). "Efficacy and Tolerability of the New Antiepileptic Drugs, I: Treatment of New-Onset Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society." Epilepsia 45(5): 401-409. <http://hdl.handle.net/2027.42/65231> | en_US |
dc.identifier.issn | 0013-9580 | en_US |
dc.identifier.issn | 1528-1167 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/65231 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15101821&dopt=citation | en_US |
dc.description.abstract | Purpose: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs [AEDs; gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS), reviewed in the order in which these agents received approval by the U.S. Food and Drug Administration] in the treatment of children and adults with newly diagnosed partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents , and Cochrane Library for relevant articles from 1987 until September 2002, with selected manual searches up to 2003. Results: Evidence exists, either from comparative or dose-controlled trials, that GBP, LTG, TPM, and OXC have efficacy as monotherapy in newly diagnosed adolescents and adults with either partial or mixed seizure disorders. Evidence also shows that LTG is effective for newly diagnosed absence seizures in children. Evidence for effectiveness of the new AEDs in newly diagnosed patients with other generalized epilepsy syndromes is lacking. Conclusions: The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with newly diagnosed epilepsy and identify those seizure types and syndromes for which more evidence is necessary. | en_US |
dc.format.extent | 97516 bytes | |
dc.format.extent | 3110 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Inc | en_US |
dc.rights | 2004 International League Against Epilepsy | en_US |
dc.subject.other | New AEDs | en_US |
dc.subject.other | New-onset Epilepsy | en_US |
dc.subject.other | Tolerability | en_US |
dc.title | Efficacy and Tolerability of the New Antiepileptic Drugs, I: Treatment of New-Onset Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | **** Department of Neurology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | * University of Pennsylvania, Philadelphia, Pennsylvania | en_US |
dc.contributor.affiliationother | † Department of Neurological Sciences, Rush Medical College, Chicago, Illinois | en_US |
dc.contributor.affiliationother | † The Cleveland Clinic Foundation, Cleveland, Ohio | en_US |
dc.contributor.affiliationother | § Vanderbilt University Medical Center, Nashville, Tennessee | en_US |
dc.contributor.affiliationother | Boston University Medical Center, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | ¶ Weill Medical College of Cornell University, New York, New York | en_US |
dc.contributor.affiliationother | ** National Institutes of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland | en_US |
dc.contributor.affiliationother | †† Columbia Presbyterian Medical Center, New York, New York | en_US |
dc.contributor.affiliationother | †† Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | §§ Children's Hospital, San Diego, California ; | en_US |
dc.contributor.affiliationother | School of Pharmacy and Department of Neurology, University of Wisconsin Hospital and Clinics, Madison, Wisconsin | en_US |
dc.contributor.affiliationother | ¶¶ University of California San Francisco Epilepsy Center, San Francisco, California | en_US |
dc.contributor.affiliationother | *** Nemours Children's Clinic, Division of Neurology, Jacksonville, Florida | en_US |
dc.contributor.affiliationother | ††† University of Illinois College of Pharmacy, Department of Pharmacy Practice and Neurology, Colleges of Pharmacy and Medicine, Chicago, Illinois | en_US |
dc.contributor.affiliationother | ††† Department of Neurology, Children's Hospital, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | §§§ Providence, Rhode Island | en_US |
dc.contributor.affiliationother | Department of Neurology, University of Alabama School of Medicine, Birmingham, Alabama | en_US |
dc.contributor.affiliationother | ¶¶¶ Department of Neurology, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey | en_US |
dc.contributor.affiliationother | †††† Department of Neurology, Children's Hospital Medical Center, Cincinnati, Ohio, U.S.A. | en_US |
dc.identifier.pmid | 15101821 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/65231/1/j.0013-9580.2004.06204.x.pdf | |
dc.identifier.doi | 10.1111/j.0013-9580.2004.06204.x | en_US |
dc.identifier.source | Epilepsia | en_US |
dc.identifier.citedreference | Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993 ; 34 : 453 – 68. | en_US |
dc.identifier.citedreference | Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940–1980. Epilepsia 1991 ; 32 : 429 – 45. | en_US |
dc.identifier.citedreference | 3. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: management issues for women with epilepsy ( summary statement ). Neurology 1998 ; 51 : 4, 944 – 8. | en_US |
dc.identifier.citedreference | Patsalos PN, Froscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy. Epilepsia 2002 ; 43 : 365 – 85. | en_US |
dc.identifier.citedreference | Isojarvi I, Rattya J, Myllyla V, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998 ; 43 : 446 – 51. | en_US |
dc.identifier.citedreference | Morrell MJ, Giudice L, Flynn KL, et al. Predictors of ovulatory failure in women with epilepsy. Ann Neurol 2002 ; 52 : 704 – 11. | en_US |
dc.identifier.citedreference | French JA. Long-term therapeutic management of epilepsy. Ann Intern Med 1994 ; 120 : 411 – 22. | en_US |
dc.identifier.citedreference | Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet 2000 ; 356 : 323 – 9. | en_US |
dc.identifier.citedreference | Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001 ; 42 : 1255 – 60. | en_US |
dc.identifier.citedreference | Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000 ; 342 : 314 – 9. | en_US |
dc.identifier.citedreference | Chadwick DW, Anhut H, Grenier MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures: International Gabapentin Monotherapy Study Group 945–77. Neurology 1998 ; 51 : 1282 – 8. | en_US |
dc.identifier.citedreference | Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy: UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995 ; 345 : 476 – 9. | en_US |
dc.identifier.citedreference | Steiner TJ, Dellaportas Cl, Findley LS, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999 ; 40 : 601 – 7. | en_US |
dc.identifier.citedreference | Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy: the UK Lamotrigine Elderly Study Group. Epilepsy Res 1999 ; 37 : 81 – 7. | en_US |
dc.identifier.citedreference | Gilliam FG, Veloso F, Bomhof MAM, et al., and the Topiramate EPMN 104 Study Group. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003 ; 60 : 196 – 201. | en_US |
dc.identifier.citedreference | Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003 ; 107 : 165 – 75. | en_US |
dc.identifier.citedreference | Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997 ; 27 : 195 – 204. | en_US |
dc.identifier.citedreference | Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997 ; 26 : 451 – 60. | en_US |
dc.identifier.citedreference | Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patient with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989 ; 3 : 70 – 6. | en_US |
dc.identifier.citedreference | Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997 ; 27 : 205 – 13. | en_US |
dc.identifier.citedreference | Frank LM, Enlow T, Holmes GL, et al. Lamictal (lamotrigine) monotherapy for typical absence seizure in children. Epilepsia 1999 ; 40 : 973 – 9. | en_US |
dc.identifier.citedreference | Trudeau V, Myers S, LaMoreaux L, et al. Gabapentin in naÏve childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol 1996 ; 11 : 470 – 5. | en_US |
dc.identifier.citedreference | Karlawish JHT, French J. Issues in drug study design: the ethical and scientific shortcomings of current monotherapy epilepsy trials in newly diagnosed patients. Epilepsy Behav 2001 ; 2 : 193 – 200. | en_US |
dc.identifier.citedreference | Patsalos PN, Froscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy. Epilepsia 2002 ; 43 : 365 – 85. | en_US |
dc.identifier.citedreference | Sabers A, Buchholt JM, Uldall P, et al. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001 ; 47 : 151 – 4. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.